G49N Stock Chart & Stats
€0.06
-€0.04(-12.73%)
At close: 4:00 PM EST
€0.06
-€0.04(-12.73%)
Day’s Range― - ―
52-Week Range€0.06 - €0.23
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€25.06M
Enterprise Value€23.78M
Total Cash (Recent Filing)€2.42M
Total Debt (Recent Filing)€12.86M
Price to Earnings (P/E)―
Beta-0.94
Next Earnings
Sep 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding235,044,330
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.62
Price to Sales (P/S)15482.52
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.08Price Target Upside33.33% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.32
Revenue Forecast (FY)€10.50M
Bulls Say, Bears Say
Bulls Say
Debt ReductionLower debt is a constructive balance-sheet development because it can reduce financing pressure and interest obligations over time. Although equity remains negative, the reduction improves financial flexibility and may help management direct more resources toward advancing the clinical pipeline.
Improving Cash BurnThe smaller operating cash outflow indicates some improvement in cash discipline relative to the prior year. Cash generation remains negative, but continued progress could extend available funding and reduce the pace at which external capital is required to support development activities.
Focused Ophthalmology PipelineA concentrated focus on severe retinal and inherited eye diseases gives GenSight a clear therapeutic identity and preserves potential value from specialized gene-therapy and optogenetics platforms. Success in these programs could create differentiated treatment opportunities in areas of high unmet need.
Bears Say
Revenue CollapseThe extreme revenue decline demonstrates that the company has very limited commercial scale and weak near-term revenue visibility. Without a meaningful recovery or successful commercialization of its pipeline, GenSight may remain dependent on financing and face difficulty converting research activity into recurring operating income.
Persistent UnprofitabilityRecurring operating and net losses indicate that the business has not yet reached an economically self-sustaining model. Continued investment without breakeven earnings increases execution risk, limits internally funded growth, and makes future financial performance highly dependent on clinical and commercial progress.
Negative Shareholders’ EquityNegative equity is a significant solvency warning because liabilities exceed recorded assets and the company has limited balance-sheet resilience. This weak capital structure can constrain strategic flexibility and increases reliance on external funding to continue operations and develop its treatments.
GenSight Biologics SA News
G49N FAQ
What was GenSight Biologics SA’s price range in the past 12 months?
GenSight Biologics SA lowest stock price was €0.06 and its highest was €0.23 in the past 12 months.
What is GenSight Biologics SA’s market cap?
GenSight Biologics SA’s market cap is €25.06M.
When is GenSight Biologics SA’s upcoming earnings report date?
GenSight Biologics SA’s upcoming earnings report date is Sep 29, 2026 which is in 20 days.
How were GenSight Biologics SA’s earnings last quarter?
GenSight Biologics SA released its earnings results on Mar 27, 2026. The company reported -€0.027 earnings per share for the quarter.
Is GenSight Biologics SA overvalued?
According to Wall Street analysts GenSight Biologics SA’s price is currently Undervalued.
Does GenSight Biologics SA pay dividends?
GenSight Biologics SA does not currently pay dividends.
What is GenSight Biologics SA’s EPS estimate?
GenSight Biologics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GenSight Biologics SA have?
GenSight Biologics SA has 235,044,330 shares outstanding.
What happened to GenSight Biologics SA’s price movement after its last earnings report?
GenSight Biologics SA reported an EPS of -€0.027 in its last earnings report. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of GenSight Biologics SA?
Currently, no hedge funds are holding shares in DE:G49N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GenSight Biologics SA
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
G49N Stock 12 Month Forecast
Average Price Target
€0.08
▲(33.33% Upside)